USRM (US Stem Cell) 3-Year Book Growth Rate: 0.00% (As of Dec. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

USRM US Stem Cell Inc USRM
12 GF Score
Price $0.00
View Full Analysis

What is US Stem Cell 3-Year Book Growth Rate?

US Stem Cell USRM 12 3-Year Book Growth Rate is 0.00% as of Dec. 2022. GuruFocus rates USRM with a GF Score™ of 12/100.

US Stem Cell's Book Value per Share for the quarter that ended in Dec. 2022 was $-0.02.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

US Stem Cell  (OTCPK:USRM) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

US Stem Cell 3-Year Book Growth Rate Related Terms

USRM vs NOVNQ, RGRX, NMTRQ: 3-Year Book Growth Rate Comparison

For the Biotechnology subindustry, US Stem Cell's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

US Stem Cell 3-Year Book Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, US Stem Cell's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where US Stem Cell's 3-Year Book Growth Rate falls into.


USRM
12GF Score
US Stem Cell Inc USRM
3-Year Book Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

US Stem Cell 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

What does a 3-Year Book Growth Rate of 0.00% mean?
US Stem Cell (USRM) has a 3-Year Book Growth Rate of 0.00% as of Dec. 2022. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for US Stem Cell and its competitors.
Is US Stem Cell's 3-Year Book Growth Rate too high?
US Stem Cell's current 3-Year Book Growth Rate is 0.00%. Overall, US Stem Cell has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does US Stem Cell's 3-Year Book Growth Rate compare to NOVNQ and RGRX?
US Stem Cell's 3-Year Book Growth Rate of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for US Stem Cell and its competitors. US Stem Cell's current 3-Year Book Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is US Stem Cell stock overvalued right now?
US Stem Cell (USRM) has a current 3-Year Book Growth Rate of 0.00%. The current 3-Year Book Growth Rate is 0.00%. US Stem Cell's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For US Stem Cell (USRM), the current 3-Year Book Growth Rate is 0.00% as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

US Stem Cell Business Description

Address 1560 Sawgrass Corporate Parkway, 4th Floor, Sunrise, FL, USA, 33323
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
12GF Score

Get the complete analysis for USRM

3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price